The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc (PSNL). (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study ...

Cervical cancer remains one of the most challenging diseases in oncology, with high recurrence rates and significant treatment side effects. For decades, the standard approach has relied on a ...

Nutritional compromise in cervical cancer patients undergoing chemoradiotherapy predicts poor survival, increased toxicity, ...

(RTTNews) - Zai Lab Limited (ZLAB) announced that China's National Medical Products Administration or NMPA has accepted the Biologics License Application or BLA for TIVDAK (tisotumab vedotin-tftv) for ...

A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence — a ...

Women with cervical cancer who experience significant muscle loss during treatment die at six times the rate of those who maintain muscle mass, according to an international review of 23 studies ...

Cervical cancer remains one of the leading causes of cancer-related deaths among women globally, despite being almost ...

“We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer,” said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at ...